Acura Pharmaceuticals IncOver The Counter Market:ACUR
- LAST PRICE0.0500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0500 / 0.0500
- Day Range
- 52 Week Range
- Volume327
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACUR |
|---|---|---|
| 12:44 ET | 220 | 0.05 |
| 02:21 ET | 100 | 0.05 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acura Pharmaceuticals Inc | 3.3M | -1.8x | --- |
Ensysce Biosciences Inc | 2.5M | 0.0x | --- |
OpGen Inc | 4.7M | -1.9x | --- |
Antigenics Inc | 28.3K | 0.0x | --- |
TC BioPharm Ltd | 4.5M | -0.3x | --- |
Drazcanna Inc | 1.2M | -0.2x | --- |
Company Information
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development and commercialization of technologies and products to address safe use of medications. The Company’s platform technologies include LIMITX Technology, AVERSION Technology and IMPEDE Technology. Its LIMITX Technology is to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provides barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Contact Information
- Headquarters
- 616 N North Ct Ste 120PALATINE, IL, United States 60067-8121
- Phone
- 847-705-7709
- Fax
- 847-705-5399
Executives
- President, Chief Executive Officer, Director
- Robert Jones
- Chief Financial Officer, Senior Vice President, Secretary
- Peter Clemens
- Vice President, Corporate Controller, Treasurer
- Robert Seiser
- Vice President - Pharmaceutical Sciences
- Albert Brzeczko
- Vice President - Corporate Development
- James Emigh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 65.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.31 |
EPS | $-0.03 |
Book Value | $-0.27 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
